Pluvicto-Induced 18 F-PSMA PET Bone Flare.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38389206.
- Also identified by DOI 10.1097/RLU.0000000000005104.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 79-year-old man with a history of metastatic prostate cancer was initially treated with Eligard and switched to relugolix in 2021. The 2022 bone scan presented superscan and extensive osseous metastatic lesions; some had intense PSMA uptake on the initial PSMA PET scan without nodal or visceral metastatic lesions. We treated him with Pluvicto and relugolix. The intermediate PSMA scan demonstrated prominent bone marrow PSMA uptake. However, PSA decreased 58.5%. We hypothesized that the patient might have a bone flare. The final PSMA scan confirmed our hypothesis. Based on our knowledge, this is the first case of Pluvicto-induced bone flare.
Medical subject headings
- Tomography, X-Ray Computed
- Bone and Bones
- Pyrimidinones